FindTrial
Sign In

1. Ensures improving the bowel movement a faster definitive diagnosis in children with acute abdominal pain? 2. CMV and HHV-6 infection associated with the development of acute appendicitis in children

1. Does supported faecal production accelerates the final diagnosis in children with acute abdominal pain? 2. Primary CMV and HHV-6 infection associated with the pathogenesis of acute appendicitis in children

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2013-000498-56-NL
Enrollment
Unknown
Registered
2013-05-16
Start date
2013-09-03
Completion date
Unknown
Last updated
2013-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

1. Acute abdominal pain 2. Appendicitis

Interventions

Trade Name: Forlax Junior 4 g, poeder voor drank in sachet Pharmaceutical Form: Powder for use in drinking water Trade Name: Forlax 10 g, poeder voor drank in sachet Pharmaceutical Form: Powder for u

Sponsors

UMCG
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: All patients between 5 and 18 years, who are referred by first line health care with the suspicion of acute appendicitis Are the trial subjects under 18? yes Number of subjects for this age range: 60 F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Severe co-morbidity like malignancy, resent abdominal surgery and known inflammatory bowl disease. Pregnancy

Design outcomes

Primary

MeasureTime frame
Main Objective: The objective of this study is to see whether a patient treating with laxantives and clysmata ensures a quicker diagnosis, which results in less abdominal pain and a better quality of life for the patient. ;Secondary Objective: Not applicable;Primary end point(s): 1. The primary outcome is the pain score given for the abdominal pain. 2. The main study endpoint is the presence of CMV or HHV-6 in the wall of the inflamed appendix, together with serology and RT-PCR for these viruses in blood samples of these patients. ;Timepoint(s) of evaluation of this end point: 1. The end point will be evaluated at the beginning and after each day with or without treatment. 2. This endpoint will be evaluated after the bloodcollection or appendectomy, as soon as possible.—

Secondary

MeasureTime frame
Secondary end point(s): 1. The secundairy endpoint is the time needed for reaching the final diagnosis. 2. The secondary endpoint is the presence of IgM and IgG antibodies against CMV and HHV-6 in the peripheral blood. To determine the proportion of primary infections and reactivations of HHV-6 and CMV in relation to the acute appendicitis.;Timepoint(s) of evaluation of this end point: 1. The end point will be evaluated at the beginning and after each day with or without treatment. 2. This endpoint will be evaluated after the bloodcollection, as soon as possible.—

Countries

Netherlands

Contacts

Public ContactPaul Broens

UMCG

p.m.a.broens@umcg.nl

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Mar 5, 2026